Comparison of Serum Levels Free and Total Prostate Specific Antigen in Women with Colorectal Cancer and Healthy Women

Document Type : Original Article(s)

Authors

1 Resident of General Surgery, Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Surgery, School of Medicine, Isfahan University of Medical sciences, Isfahan, Iran

10.48305/jims.v42.i770.0463

Abstract

Background: Prostate-specific antigen has been reported in non-prostate cancer tissues such as the breast, ovary, endometrium, kidney, adrenal, liver, salivary glands, and esophagus, as well as in colon cancer tissues. The study aimed to compare the serum level of the above antigen in women with colorectal cancer and the control group.
Methods: In this case-control study, 17 female patients with colorectal cancer and 17 healthy women who were admitted to Al-Zahra Hospital in Isfahan during 2021-2022 were selected and compared in terms of prostate-specific antigen levels.
Findings: The median free PSA level in the case group was 0.01 (0.005-0.01), and in the control group was 0.008 (0.007-0.009) (P < 0.001), and the median total PSA level in the two groups was 0.012 (0.007-0.04) and 0.001 (0.001-0.005) ng/dL, respectively (P > 0.001) and the difference between the two groups was significant.
Conclusion: In this study, total and free PSA levels in women with colorectal cancer were significantly higher than healthy women. Total and free PSA serum levels decreased with age, but this inverse correlation was not statistically significant. There was no significant correlation between total and free PSA serum levels and the location or stage of tumors. Measurement of PSA level in women with colorectal cancer may be helpful in the diagnosis of biopsy and applicable for early diagnosis of the disease.

Highlights

Gholamreza Mohajeri: PubMed, Google Scholar

Amirtaher Taebi: PubMed, Google Scholar

Keywords

Main Subjects

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
  2. Lauby-Secretan B, Vilahur N, Straif K. IARC Handbook of Cancer Prevention Vol. 17 - Colorectal Cancer Screening. Vol. 4, Journal of Global Oncology 2018. p. 51s-51s.
  3. Mohajeri G, Mohajeri MR, Afshar-Moghaddam N, Aslanpour A. The significance of clinicopathological aspects of tumor for the detection of liver micrometastasis in patients with colorectal cancer. J Res Med Sci 2014; 19(5): 410-3.
  4. Richardson LC, King JB, Thomas CC, Richards TB, Dowling NF, King SC. Adults who have never been screened for colorectal cancer, behavioral risk factor surveillance system, 2012 and 2020. Prev Chronic Dis 2022; 19: E21.
  5. Simpson BS. Evaluating novel prognostic biomarkers in prostate cancer [Thesis]. Gower St, London: UCL University College London ; 2022. P. 760.
  6. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA 2003; 289(11): 1414-20.
  7. Mohajeri G, Jafarpisheh M, Kaviani H. Diagnostic values of serum total prostate-specific antigen for detection of breast masses nature in 20-75-year-old women with breast mass [in Persian]. J Isfahan Med Sch 2017; 35(439): 870-57.
  8. Duraker N, Çaynak ZC, Trabulus DC. Free/total serum prostate-specific antigen ratio in women with colorectal cancer has prognostic significance. J Gastrointest Cancer 2017; 48(1): 8-12.
  9. Das S, Paul R, De U, Mukhopadhyay M. The lady with raised prostate specific antigen: do we need to worry? Asian Pac J Cancer Prev 2011; 12(8): 2051-3.
  10. Mashkoor FC, Al-Asadi JN, Al-Naama LM. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol 2013; 37(5): 613-8.
  11. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19(3): 329-59.
  12. Fedewa SA, Yabroff KR, Smith RA, Goding Sauer A, Han X, Jemal A. Changes in breast and colorectal cancer screening after Medicaid expansion under the

    Affordable Care Act. Am J Prev Med 2019; 57(1): 3-12.
  13. Lemon S, Zapka J, Puleo E, Luckmann R, Chasan-Taber L. Colorectal cancer screening participation: comparisons with mammography and prostate-specific antigen screening. Am J Public Health 2001; 91(8): 1264-72.
  14. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40(12): 1754-61.
Journal of Isfahan Medical School
Volume 42, Issue 770
2nd Week, August
July and August 2024
Pages 463-468

Files

History

  • Receive Date: 04 May 2024
  • Accept Date: 18 August 2024

Share

How to cite

Statistics